Mastek Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/z6ve792d1z5amlmhjcen1nks.pdf

Key Takeaways


UK & Europe: The Growth Engine

Umang Nahata: "there's nothing that we have heard so far, which would made us think in any view that we derail from where our current path was as far as NHS is concerned. So we are optimistic for a significant growth even in the next year."

North America: Reset Underway


Margins: The Price of Capability Build

Umang Nahata: "No, that doesn't change at all. Our ambition and drive is to drive to 17% to 19%. Like I said, there are some fundamental correction that we have made now. A lot of it is a cost of reset also. Some of it is also driving business in the right capability areas in U.K. as well as in U.S. So these will need some fundamental time to correct. But I'm sure before we end the next year, we will be in that range of 17% to 19%."

Data & AI: The Bet Being Built

Umang Nahata: "We've already seen customers where we are seeing more than 30% efficiency benefits as we are executing, especially the fixed bid projects that we execute across Oracle, Digital and Salesforce using AI and AI-enabled technologies."

Order Book & Deal Dynamics


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginReach 17% to 19% rangeBefore end of FY26
UK Healthcare growthSignificantly high growth to continueFY26
UK margins recoveryReturn to healthy margin rates as on-site/offshore mix improvesMidterm, over next year
Subcontractor balance70–80 new subcontractors added this quarter to be balanced outComing 2–3 quarters
AI-driven internal efficiency15% to 20% efficiency drive from AI adoption in deliveryOngoing
Blue Cross Blue Shield MSAsAdd a few more MSAs beyond BCBSNext 1–2 quarters
Cerner investmentInvest when Oracle opens Cerner for partnersNo date (conditional on Oracle)

Key Metrics

MetricQ4 FY25
Revenue from operations (FY25)13.1% growth, compared to FY24
Net profit (FY25)20.9% growth, compared to FY24
Cash and cash equivalents₹622 cr, up from ₹473 cr at end of FY24
Final dividend₹16 per share, cumulative 460% for FY25
EBITDAde-grew 1.4% QoQ; impacted by lower-margin new business, one-time reset costs, and lower US revenue
Net profitde-grew 14.4% QoQ; includes a one-time prior period cost adjustment
UK and Europe revenue17.2% growth YoY and 9.4% growth QoQ
North America revenue~16% growth YoY, 8% decline QoQ; macro uncertainty and in-sourcing by some clients
Oracle business (North America)more than 50% growth in FY25 compared to FY24
UK healthcare businessmore than 100% growth YoY in FY25
12-month order backlog1.7% growth for FY25; would be closer to 7-8% including a $15M ACV contract closed in first week of April
Total active customers (North America)120-plus
New customers added11 in Q4; targeting 40-50 annually while reducing tail customers
Subcontractors added70-80 new subcontractors in Q4
DSO83 days, improved from 81 days earlier in the fiscal; target for the fiscal achieved
Cash generationmore than 30% growth YoY
Data and AI team size200-250-plus people, adding another 50-100
AI-led use cases developedmore than 100
AI efficiency benefit on fixed-bid projectsmore than 30% efficiency benefits observed
ADOPT.AI platform efficiency30% to 50% efficiency offered to customers
Internal AI adoption efficiency target15% to 20% efficiency drive targeted
NHS England merger timelineat least 2 years for integration